These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 19474475)

  • 21. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
    Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
    J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.
    Knapp DJ; Brumme ZL; Huang SY; Wynhoven B; Dong WW; Mo T; Harrigan PR; Brumme CJ
    Clin Infect Dis; 2012 Jun; 54(11):1652-9. PubMed ID: 22460975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.
    Masquelier B; Capdepont S; Neau D; Peuchant O; Taupin JL; Coakley E; Lie Y; Carpentier W; Dabis F; Fleury HJ;
    AIDS; 2007 Jan; 21(1):103-6. PubMed ID: 17148975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
    Chaiwarith R; Wachirakaphan C; Kotarathititum W; Praparatanaphan J; Sirisanthana T; Supparatpinyo K
    Int J Infect Dis; 2007 Sep; 11(5):413-6. PubMed ID: 17331776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiretroviral therapy failure and HIV super-infection.
    Bezemer D; van Sighem A; de Wolf F; Cornelissen M; van der Kuyl AC; Jurriaans S; van der Hoek L; Prins M; Coutinho RA; Lukashov VV
    AIDS; 2008 Jan; 22(2):309-11. PubMed ID: 18097235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
    Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.
    Mildvan D; Bosch RJ; Kim RS; Spritzler J; Haas DW; Kuritzkes D; Kagan J; Nokta M; DeGruttola V; Moreno M; Landay A
    J Infect Dis; 2004 May; 189(10):1811-20. PubMed ID: 15122517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
    Makinson A; Masquelier B; Taieb A; Peytavin G; Waldner-Combernoux A; Collin G; Chêne G; Brun-Vézinet F; Raffi F; Le Moing V; Leport C; Descamps D
    AIDS; 2006 Jun; 20(9):1327-9. PubMed ID: 16816563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.
    Lambert JS; Machado ES; Watson DC; Sill AM; Lim JK; Charurat M; Cunha SM; Afonso AO; Oliviera RH; Tanuri A; DeVico AL
    Pediatr Infect Dis J; 2007 Oct; 26(10):935-44. PubMed ID: 17901800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.
    Mologni D; Citterio P; Menzaghi B; Zanone Poma B; Riva C; Broggini V; Sinicco A; Milazzo L; Adorni F; Rusconi S; Galli M; Riva A;
    AIDS; 2006 Feb; 20(4):567-74. PubMed ID: 16470121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.